Release Forms:


  • active substance: doxylamine;
  • 1 tablet contains 15 mg doxylamine succinate;
  • excipients: lactose, monohydrate; sodium croscarmellose; microcrystalline cellulose; magnesium stearate; Sele CoatTM coating (hypromellose, polyethylene glycol (macrogol) 6000, titanium dioxide (E 171)).

Dosage form. Film-coated tablets.

Basic physical and chemical properties: round tablets with a biconvex surface, coated with a white shell, two layers are visible on the break.

10 tablets in a blister; 1 or 3 blisters in a box.

10 tablets in a blister; 1 or 3 blisters in a box.

Indications for use.

Antihistamines for systemic use. Hypnotics and sedatives.

Recurrent insomnia in adults.


Hypersensitivity to doxylamine succinate or to excipients and other antihistamines.
History of acute angle-closure glaucoma or family history.
Urethroprostatic disorders with a risk of urinary retention.

Method of application.

For oral administration. Apply 15-30 minutes before bedtime.
The recommended dose is 7.5–15 mg per day (½ – 1 tablet per day). If necessary, the dose can be increased to 30 mg per day (2 tablets per day).
Elderly patients and patients with renal or hepatic insufficiency are advised to reduce the dose.
The duration of the course of treatment is 2–5 days.
If insomnia persists for more than 5 days, you should consult your doctor regarding the appropriateness of further use of the drug.

The drug should not be used in children under 18 years of age.